Michał Kaza
Michał Kaza has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Piotr Józef Rudzki
Celon Pharma S.A., Bioanalytical Laboratory, 15 Marymoncka, 05-152 Kazuń Nowy, Poland
16 shared publications - Przemyslaw Biecek
Faculty of Mathematics and Information Science, Warsaw University of Technology, Warsaw, Poland
3 shared publications - Tomasz Pawiński
Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
3 shared publications - Agnieszka Gierczak-Pachulska
Celon Pharm SA, R&D Ctr, Ul Marymoncka 15, PL-05152 Kazun Nowy, Poland
2 shared publications - Agnieszka Segiet
Faculty and Department of Experimental Physiology, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
2 shared publications Anna Szlagowska
2 shared publications
Latest Publications
- Open Access
- 24 June 2025
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 82 (1) , 37-48
Relative Bioavailability of Ticagrelor from Hard Capsules and Film-Coated Tablets in Healthy Caucasian Volunteers
Ticagrelor is an active pharmaceutical ingredient of the first oral medicinal product inhibiting adenosine diphosphate-induced platelet aggregation by reversibly binding to P2Y12 receptor. It is co-administered with acetylsalicylic acid in patients with acute coronary syndromes or a history of myocardial infarction with high risk of cardiovascular events. The aim of study was to evaluate relative bioavailability of ticagrelor from two oral pharmaceutical forms hard capsules (Tikozek, test product) vs. film-coated tablets (Brilique®, reference product) after a single 90 mg dose administration. A randomized, 2-period, crossover, open-label, and laboratory-blinded study was conducted in healthy Caucasian male and female volunteers in Poland. Ticagrelor in human plasma was quantified by a validated LC-MS/MS method using isotope labelled internal standard. Two pharmaceutical forms were considered bioequivalent when 90% confidence intervals (CI) of the log-transformed geometric mean ratios (hard capsules over film-coated tablets) for both AUC(0-t) and Cmax were within 80.00-125.00%. Adverse events, values of laboratory parameters, and vital signs were recorded during the study. Among 40 volunteers enrolled, 37 completed the study. Geometric mean ratios for the primary pharmacokinetic parameter were 100.51% (90% CI 95.00-106.34%) for AUC(0-t), and 92.43% (90% CI 84.11-101.58%) for Cmax. Ticagrelor administered in both pharmaceutical forms was well tolerated. No serious adverse events were recorded. Results of the clinical trial indicate that hard capsules (Tikozek) are bioequivalent to the film-coated tablets (Brilique®).
- 24 June 2025
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 82 (1) , 37-48
Open AccessRelative Bioavailability of Ticagrelor from Hard Capsules and Film-Coated Tablets in Healthy Caucasian Volunteers
Ticagrelor is an active pharmaceutical ingredient of the first oral medicinal product inhibiting adenosine diphosphate-induced platelet aggregation by reversibly binding to P2Y12 receptor. It is co-administered with acetylsalicylic acid in patients with acute coronary syndromes or a history of myocardial infarction with high risk of cardiovascular events. The aim of study was to evaluate relative bioavailability of ticagrelor from two oral pharmaceutical forms hard capsules (Tikozek, test product) vs. film-coated tablets (Brilique®, reference product) after a single 90 mg dose administration. A randomized, 2-period, crossover, open-label, and laboratory-blinded study was conducted in healthy Caucasian male and female volunteers in Poland. Ticagrelor in human plasma was quantified by a validated LC-MS/MS method using isotope labelled internal standard. Two pharmaceutical forms were considered bioequivalent when 90% confidence intervals (CI) of the log-transformed geometric mean ratios (hard capsules over film-coated tablets) for both AUC(0-t) and Cmax were within 80.00-125.00%. Adverse events, values of laboratory parameters, and vital signs were recorded during the study. Among 40 volunteers enrolled, 37 completed the study. Geometric mean ratios for the primary pharmacokinetic parameter were 100.51% (90% CI 95.00-106.34%) for AUC(0-t), and 92.43% (90% CI 84.11-101.58%) for Cmax. Ticagrelor administered in both pharmaceutical forms was well tolerated. No serious adverse events were recorded. Results of the clinical trial indicate that hard capsules (Tikozek) are bioequivalent to the film-coated tablets (Brilique®).
- Open Access
- 9 April 2024
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 81 (1) , 97-108
Bioequivalence of Rivaroxaban Hard Capsules vs. Film-Coated Tablets in Healthy White Volunteers
- 9 April 2024
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 81 (1) , 97-108
Open AccessBioequivalence of Rivaroxaban Hard Capsules vs. Film-Coated Tablets in Healthy White Volunteers
- 1 November 2021
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 206, 114362
LC-MS/MS determination of dutasteride and its major metabolites in human plasma
- 1 November 2021
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 206, 114362
LC-MS/MS determination of dutasteride and its major metabolites in human plasma
- Open Access
- 13 July 2020
- Published by Springer Nature in Pharmaceutical Research
- Vol. 37 (7) , 1-5
10th Anniversary of a Two-Stage Design in Bioequivalence. Why Has it Still Not Been Implemented?
Purpose: In 2010 the European Medicines Agency allowed a two-stage design in bioequivalence studies. However, in the public domain there are mainly articles describing the theoretical and statistical base for the application of the two-stage design. One of the reasons seems to be the lack of practical guidance for the Sponsors on when and how the two-stage design can be beneficial in bioequivalence studies. Methods: Different variants with positive and negative outcomes have been evaluated, including a pivotal study, pilot + pivotal study and two-stage study. The scientific perspective on the two-stage bioequivalence study has been confronted with the industrial one. Results: Key information needed to conduct a bioequivalence study – such as in vitro data and pharmacokinetics – have been listed and organized into a decision scheme. Advantages and disadvantages of the two-stage design have been summarized. Conclusion: The use of the two-stage design in bioequivalence studies seems to be a beneficial alternative to the 2 × 2 crossover study. Basic information on the properties of the active substance and the characteristics of the drug form are needed to make an initial decision to carry out the two-stage study.
- 13 July 2020
- Published by Springer Nature in Pharmaceutical Research
- Vol. 37 (7) , 1-5
Open Access10th Anniversary of a Two-Stage Design in Bioequivalence. Why Has it Still Not Been Implemented?
Purpose: In 2010 the European Medicines Agency allowed a two-stage design in bioequivalence studies. However, in the public domain there are mainly articles describing the theoretical and statistical base for the application of the two-stage design. One of the reasons seems to be the lack of practical guidance for the Sponsors on when and how the two-stage design can be beneficial in bioequivalence studies. Methods: Different variants with positive and negative outcomes have been evaluated, including a pivotal study, pilot + pivotal study and two-stage study. The scientific perspective on the two-stage bioequivalence study has been confronted with the industrial one. Results: Key information needed to conduct a bioequivalence study – such as in vitro data and pharmacokinetics – have been listed and organized into a decision scheme. Advantages and disadvantages of the two-stage design have been summarized. Conclusion: The use of the two-stage design in bioequivalence studies seems to be a beneficial alternative to the 2 × 2 crossover study. Basic information on the properties of the active substance and the characteristics of the drug form are needed to make an initial decision to carry out the two-stage study.
- 28 April 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (7) , 427-429
Visualizing Bioanalytical Methods – a Near or Distant Future?
- 28 April 2020
- Published by Taylor & Francis in Bioanalysis
- Vol. 12 (7) , 427-429
Visualizing Bioanalytical Methods – a Near or Distant Future?
- Open Access
- 11 February 2019
- Published by Springer Nature in The AAPS Journal
- Vol. 21 (2) , 1-8
Incurred Sample Reanalysis: Time to Change the Sample Size Calculation?
Reliable results of pharmacokinetic and toxicokinetic studies are vital for correct decision making during drug discovery and development. Thus, ensuring h
- 11 February 2019
- Published by Springer Nature in The AAPS Journal
- Vol. 21 (2) , 1-8
Open AccessIncurred Sample Reanalysis: Time to Change the Sample Size Calculation?
Reliable results of pharmacokinetic and toxicokinetic studies are vital for correct decision making during drug discovery and development. Thus, ensuring h
- Top Cited PapersOpen Access
- 1 February 2019
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 165, 381-385
Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?
- 1 February 2019
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 165, 381-385
Top Cited PapersOpen AccessBioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?
- 1 February 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (3) , 153-162
Extended 3D and 4D cumulative plots for evaluation of unmatched incurred sample reanalysis
Aim: Incurred sample reanalysis (ISR) helps ensure the reliability of pharmacokinetic studies. An appropriate graph may facilitate the evaluation of an unmatched reanalyses or a failed ISR test. Methods: We evaluated different ways of visualizing multidimensional ISR data using an extended cumulative ISR plot. Results: 3D and 4D cumulative ISR plots enable comprehensive data analysis using a single plot. We propose to use color for percentage difference classes in bar and XY-scatter plots. For the latter the shape of symbols may represent analyte concentration class, study phase, analyst or subject. Conclusion: The extended 3D and 4D cumulative ISR plots facilitate in-study monitoring and post-study inspection of data. It helps find the root cause of unmatched ISR, thus increasing reliability of bioanalytical data.
- 1 February 2018
- Published by Taylor & Francis in Bioanalysis
- Vol. 10 (3) , 153-162
Extended 3D and 4D cumulative plots for evaluation of unmatched incurred sample reanalysis
Aim: Incurred sample reanalysis (ISR) helps ensure the reliability of pharmacokinetic studies. An appropriate graph may facilitate the evaluation of an unmatched reanalyses or a failed ISR test. Methods: We evaluated different ways of visualizing multidimensional ISR data using an extended cumulative ISR plot. Results: 3D and 4D cumulative ISR plots enable comprehensive data analysis using a single plot. We propose to use color for percentage difference classes in bar and XY-scatter plots. For the latter the shape of symbols may represent analyte concentration class, study phase, analyst or subject. Conclusion: The extended 3D and 4D cumulative ISR plots facilitate in-study monitoring and post-study inspection of data. It helps find the root cause of unmatched ISR, thus increasing reliability of bioanalytical data.
- 31 October 2017
- Published by Taylor & Francis in Bioanalysis
- Vol. 9 (21) , 1719-1726
Incurred sample reanalysis: adjusted procedure for sample size calculation
Aim: The incurred sample reanalysis (ISR) helps to assure bioanalysis reliability. The regulatory guidelines recommend the reanalysis of up to 10% of the study samples for this test, but not all reanalyses are necessary to evaluate the test result. Materials & methods: We have optimized ISR sample size calculation to eliminate negligible reanalyses. Results: Adjusted procedure eliminates negligible reanalyses - up to 66% of currently analyzed ISRs - without affecting the test outcome. Conclusion: The procedure is universal as it may be applied in the studies compliant with EMA and US FDA requirements, for both small and large molecules. It may assist the evolution of bioanalytical method validation as the current ISR sample size recommendations seem to be ill-matched with the acceptance criteria.
- 31 October 2017
- Published by Taylor & Francis in Bioanalysis
- Vol. 9 (21) , 1719-1726
Incurred sample reanalysis: adjusted procedure for sample size calculation
Aim: The incurred sample reanalysis (ISR) helps to assure bioanalysis reliability. The regulatory guidelines recommend the reanalysis of up to 10% of the study samples for this test, but not all reanalyses are necessary to evaluate the test result. Materials & methods: We have optimized ISR sample size calculation to eliminate negligible reanalyses. Results: Adjusted procedure eliminates negligible reanalyses - up to 66% of currently analyzed ISRs - without affecting the test outcome. Conclusion: The procedure is universal as it may be applied in the studies compliant with EMA and US FDA requirements, for both small and large molecules. It may assist the evolution of bioanalytical method validation as the current ISR sample size recommendations seem to be ill-matched with the acceptance criteria.
- 19 June 2017
- Published by Taylor & Francis in Bioanalysis
- Vol. 9 (12) , 947-956
Comprehensive Graphical Presentation of Data from Incurred Sample Reanalysis
Aim: Incurred sample reanalysis (ISR) contributes to the reliability of pharmacokinetic studies. Despite regulatory guidelines having adopted ISR methodology, graphical presentation of data has been overlooked. Materials & methods: Different graphs were tested for datasets including limited, standard and large numbers of ISR pairs. The datasets covered both passed and failed cases. Results: We have developed a combination of complementary plots enabling the visual inspection of ISR data quality: %difference versus mean concentration and cumulative ISR plot. The former shows individual ISR datapoints and concentration-dependent trends, while the latter presents the contribution of individual pairs to the overall result as well as time-dependent trends. Conclusion: The proposed visualization of ISR data shows at a glance whether acceptance criteria for each sample and whole experiment are met or not. Standardized graphical presentation of ISR outcomes may increase quality of bioanalytical data.
- 19 June 2017
- Published by Taylor & Francis in Bioanalysis
- Vol. 9 (12) , 947-956
Comprehensive Graphical Presentation of Data from Incurred Sample Reanalysis
Aim: Incurred sample reanalysis (ISR) contributes to the reliability of pharmacokinetic studies. Despite regulatory guidelines having adopted ISR methodology, graphical presentation of data has been overlooked. Materials & methods: Different graphs were tested for datasets including limited, standard and large numbers of ISR pairs. The datasets covered both passed and failed cases. Results: We have developed a combination of complementary plots enabling the visual inspection of ISR data quality: %difference versus mean concentration and cumulative ISR plot. The former shows individual ISR datapoints and concentration-dependent trends, while the latter presents the contribution of individual pairs to the overall result as well as time-dependent trends. Conclusion: The proposed visualization of ISR data shows at a glance whether acceptance criteria for each sample and whole experiment are met or not. Standardized graphical presentation of ISR outcomes may increase quality of bioanalytical data.